Is Tango Therapeutics Stock a Good Investment?
Tango Therapeutics Investment Advice | TNGX |
- Examine Tango Therapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Tango Therapeutics' leadership team and their track record. Good management can help Tango Therapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Tango Therapeutics' business and its evolving consumer preferences.
- Compare Tango Therapeutics' performance and market position to its competitors. Analyze how Tango Therapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if Tango Therapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Tango Therapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Tango Therapeutics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Tango Therapeutics is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Relatively risky | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Moves completely opposite to the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Tango Therapeutics Stock
Researching Tango Therapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 13.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 1.85. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Tango Therapeutics recorded a loss per share of 1.15. The entity had not issued any dividends in recent years.
To determine if Tango Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Tango Therapeutics' research are outlined below:
| Tango Therapeutics generated a negative expected return over the last 90 days | |
| Tango Therapeutics has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 36.53 M. Net Loss for the year was (101.74 M) with loss before overhead, payroll, taxes, and interest of (81.05 M). | |
| Tango Therapeutics currently holds about 416.36 M in cash with (117.98 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.73, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Tango Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Over 87.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Tango Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference |
Tango Therapeutics Quarterly Cost Of Revenue |
|
Tango Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Tango Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Tango Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 25th of March 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 25th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Tango Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Tango Therapeutics' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2021-08-06 | 2021-06-30 | -0.145 | -0.16 | -0.015 | 10 | ||
2024-05-08 | 2024-03-31 | -0.31 | -0.35 | -0.04 | 12 | ||
2024-03-18 | 2023-12-31 | -0.28 | -0.32 | -0.04 | 14 | ||
2022-08-10 | 2022-06-30 | -0.32 | -0.28 | 0.04 | 12 | ||
2024-11-06 | 2024-09-30 | -0.37 | -0.27 | 0.1 | 27 | ||
2024-08-07 | 2024-06-30 | -0.34 | -0.24 | 0.1 | 29 | ||
2023-11-08 | 2023-09-30 | -0.34 | -0.23 | 0.11 | 32 | ||
2023-08-07 | 2023-06-30 | -0.34 | -0.23 | 0.11 | 32 |
Know Tango Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Tango Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Tango Therapeutics backward and forwards among themselves. Tango Therapeutics' institutional investor refers to the entity that pools money to purchase Tango Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Balyasny Asset Management Llc | 2024-09-30 | 2.7 M | State Street Corp | 2024-09-30 | 2.3 M | Adage Capital Partners Gp Llc | 2024-09-30 | 2.3 M | Deerfield Management Co | 2024-09-30 | 1.5 M | Geode Capital Management, Llc | 2024-09-30 | 1.4 M | Casdin Capital, Llc | 2024-09-30 | 1.2 M | Baker Bros Advisors Lp | 2024-09-30 | 750 K | Arrowmark Colorado Holdings, Llc (arrowmark Partners) | 2024-09-30 | 708.4 K | Bessemer Group Inc | 2024-09-30 | 708.4 K | Trv Gp Iv, Llc | 2024-09-30 | 16.9 M | Ecor1 Capital, Llc | 2024-09-30 | 13.3 M |
Tango Therapeutics' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 438.27 M.Market Cap |
|
Tango Therapeutics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.25) | (0.27) | |
| Return On Capital Employed | (0.32) | (0.34) | |
| Return On Assets | (0.25) | (0.27) | |
| Return On Equity | (0.40) | (0.42) |
Determining Tango Therapeutics' profitability involves analyzing its financial statements and using various financial metrics to determine if Tango Therapeutics is a good buy. For example, gross profit margin measures Tango Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Tango Therapeutics' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Tango Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Tango Therapeutics. Check Tango Therapeutics' Beneish M Score to see the likelihood of Tango Therapeutics' management manipulating its earnings.
Evaluate Tango Therapeutics' management efficiency
Tango Therapeutics has return on total asset (ROA) of (0.2237) % which means that it has lost $0.2237 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4879) %, meaning that it created substantial loss on money invested by shareholders. Tango Therapeutics' management efficiency ratios could be used to measure how well Tango Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.27 in 2024. Return On Capital Employed is likely to drop to -0.34 in 2024. At this time, Tango Therapeutics' Net Tangible Assets are fairly stable compared to the past year. Asset Turnover is likely to rise to 0.15 in 2024, whereas Total Assets are likely to drop slightly above 352.5 M in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 2.68 | 2.10 | |
| Tangible Book Value Per Share | 2.68 | 2.14 | |
| Enterprise Value Over EBITDA | (8.13) | (8.54) | |
| Price Book Value Ratio | 3.70 | 6.45 | |
| Enterprise Value Multiple | (8.13) | (8.54) | |
| Price Fair Value | 3.70 | 6.45 | |
| Enterprise Value | 908.8 M | 954.2 M |
At Tango Therapeutics, effective management practices are pivotal to sustaining long-term profitability. We delve into financial metrics and market conditions to provide a comprehensive analysis of the stock's prospects.
Beta 0.879 |
Basic technical analysis of Tango Stock
As of the 2nd of December, Tango Therapeutics has the Coefficient Of Variation of (554.60), variance of 51.8, and Risk Adjusted Performance of (0.13). In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Tango Therapeutics, as well as the relationship between them.Tango Therapeutics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Tango Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Tango Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Tango Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Tango Therapeutics' Outstanding Corporate Bonds
Tango Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Tango Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Tango bonds can be classified according to their maturity, which is the date when Tango Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Volcan Compania Minera Corp BondUSP98047AC08 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| International Game Technology Corp BondUS460599AD57 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View |
Understand Tango Therapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Tango Therapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.13) | |||
| Market Risk Adjusted Performance | 0.5215 | |||
| Mean Deviation | 4.82 | |||
| Coefficient Of Variation | (554.60) | |||
| Standard Deviation | 7.2 | |||
| Variance | 51.8 | |||
| Information Ratio | (0.20) | |||
| Jensen Alpha | (0.98) | |||
| Total Risk Alpha | (2.51) | |||
| Treynor Ratio | 0.5115 | |||
| Maximum Drawdown | 45.2 | |||
| Value At Risk | (11.03) | |||
| Potential Upside | 7.75 | |||
| Skewness | (1.87) | |||
| Kurtosis | 8.94 |
| Risk Adjusted Performance | (0.13) | |||
| Market Risk Adjusted Performance | 0.5215 | |||
| Mean Deviation | 4.82 | |||
| Coefficient Of Variation | (554.60) | |||
| Standard Deviation | 7.2 | |||
| Variance | 51.8 | |||
| Information Ratio | (0.20) | |||
| Jensen Alpha | (0.98) | |||
| Total Risk Alpha | (2.51) | |||
| Treynor Ratio | 0.5115 | |||
| Maximum Drawdown | 45.2 | |||
| Value At Risk | (11.03) | |||
| Potential Upside | 7.75 | |||
| Skewness | (1.87) | |||
| Kurtosis | 8.94 |
Consider Tango Therapeutics' intraday indicators
Tango Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Tango Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Tango Therapeutics Corporate Filings
13A | 20th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
F4 | 18th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 6th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F3 | 22nd of October 2024 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
Tango Stock media impact
Far too much social signal, news, headlines, and media speculation about Tango Therapeutics that are available to investors today. That information is available publicly through Tango media outlets and privately through word of mouth or via Tango internal channels. However, regardless of the origin, that massive amount of Tango data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Tango Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Tango Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Tango Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Tango Therapeutics alpha.
Tango Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Tango Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Tango Therapeutics Corporate Management
| MD Kaelin | Founder Board | Profile | |
| Antoni MD | Founder Board | Profile | |
| Daniella CPA | Chief Officer | Profile | |
| Alan Huang | Chief Officer | Profile | |
| Levi MD | Founder | Profile | |
| JD Esq | Chief Counsel | Profile |
Additional Tools for Tango Stock Analysis
When running Tango Therapeutics' price analysis, check to measure Tango Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tango Therapeutics is operating at the current time. Most of Tango Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tango Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tango Therapeutics' price. Additionally, you may evaluate how the addition of Tango Therapeutics to your portfolios can decrease your overall portfolio volatility.